Serpiginous Choroidopathy

Ali Istanaksai

Introduction

Serpiginous choroidopathy (SC) is a rare, chronic, bilateral, and progressive inflammatory disorder caused by destruction of the retinal pigment epithelium (RPE), choriocapillaris, and choroid. It is a cause of permanent visual loss, and accounts for less than 5% of posterior uveitis cases. SC typically affects young to middle-aged adults, with a male predominance (1). This article aims to provide an overview of the pathophysiology, clinical features, diagnosis and management of SC.

Pathophysiology

Whilst the aetiology remains uncertain, an autoimmune or immunogenic mechanism is strongly suspected due to the disease’s responsiveness to corticosteroids and immunosuppressants. Genetic studies have found increased frequency of HLA-B7 in affected individuals. Possible links to Mycobacterium tuberculosis and herpes viruses have also been proposed but not yet proven (2).

Clinical features

Patients usually present with painless unilateral vision loss, metamorphopsia, or a central scotoma. Clinical signs include cream coloured subretinal infiltrates that originate from the peripapillary region and spread centrifugally. These infiltrates are described as spreading in a ‘serpiginous’ manner. These lesions resolve and leave behind areas of RPE and choriocapillary atrophy. Recurrence of active lesions may range from months to years, and whilst SC is bilateral, the disease is often asymmetrical, and lesions may display varying stages of activity. Over time, recurrent activity leads to patchy RPE and choriocapillary atrophy as highlighted by areas of hypo and hyperpigmented lesions over the posterior fundus. These retinal changes result in irreversible visual loss (2).

Investigations

The diagnosis of SC remains clinical as there are no specific diagnosis tests available (3). However, fluorescein angiography (FA), indocyanine green angiography (ICG) and fundus autofluorescence (FAF) are used to aid diagnosis. Active lesions typically show early hypo fluorescence with late leakage on FA and hyperautofluorescent borders on FAF (1). Important differential diagnoses include other aetiologies of posterior uveitis. Notably, tuberculosis (TB) has been linked to a choroidopathy resembling SC, commonly referred to as serpiginous-like choroidopathy (SLC). TB testing is therefore vital as these diseases may appear similar but have very different therapeutic approaches (1).

Management

The mainstay of treatment is controlling inflammation and preventing recurrences through the use of systemic corticosteroids with steroid-sparing immunosuppressive agents such as methotrexate, mycophenolate mofetil, azathioprine, cyclosporine, or anti-TNF agents (e.g., adalimumab, infliximab) once tuberculosis has been excluded (4).

Complications include choroidal neovascularization (up to 35% of cases), macular oedema, subretinal fibrosis, and optic disc neovascularization, all of which can lead to significant visual loss. Long-term prognosis is guarded, with approximately one-quarter of affected eyes reaching a final visual acuity below 20/200 despite treatment (1).

References

  1. Guedes M, Serpiginous choroidopathy Internet). EyeWiki; 2025 (cited 2025 Oct 20).
  2. Gupta, V., Gupta, A., Arora, S., Bambery, P., Dogra, M.R. and Agarwal, A., 2003. Presumed tubercular serpiginouslike choroiditis: clinical presentations and management. Ophthalmology, 110(9), pp.1744-1749.
  3. Baglivo, E., Boudjema, S., Pieh, C., Safran, A.B., Chizzolini, C., Herbort, C. and Rao, N., 2005. Vascular occlusion in serpiginous choroidopathy. British Journal of Ophthalmology, 89(3), pp.387–388. doi:10.1136/bjo.2004.052126.
  4. Akpek, E.K., Jabs, D.A., Tessler, H.H., Joondeph, B.C. and Foster, C.S., 2002. Successful treatment of serpiginous choroiditis with alkylating agents. Ophthalmology, 109(8), pp.1506-1513.

Leave a Reply